TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 14743647

Group type: EXPERIMENTAL
Intervention: High-dose steroids (30 mg/kg/d of methylprednisolone for three to five days with a six-week taper)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low-dose steroids
Number of subjects: 0

Group type: COMPARATOR
Intervention: Steroids (general use)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nontreatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Treatments studied in adults (applied to children with MS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Recurrence of ADEM
Number of subjects: 0

Group type: COMPARATOR
Intervention: Long-term outcome of childhood MS
Number of subjects: 0
Study: 10817948

Group type: EXPERIMENTAL
Intervention: Linguagraph (used for therapy and assessment)
Number of subjects: 0
Study: 8899316

Group type: EXPERIMENTAL
Intervention: Ukrain
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control (no Ukrain)
Number of subjects: 10
Study: 1355149

Group type: EXPERIMENTAL
Intervention: Ramipril 5 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 6096349

Group type: EXPERIMENTAL
Intervention: Ampicillin (500 mg) plus sulbactam (500 mg)
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: Ampicillin (500 mg) plus metronidazole (1 g suppository)
Number of subjects: 295

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: Other types of operation
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: Treatment groups (A + B)
Number of subjects: 295
Study: 29619794

Group type: EXPERIMENTAL
Intervention: Fitness app usage for two weeks
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control condition (no information about mobile apps)
Number of subjects: 78
Study: 30388149

Group type: EXPERIMENTAL
Intervention: Dietary diversity score of <4 food groups
Number of subjects: 389

Group type: EXPERIMENTAL
Intervention: Age group of 12-14 years
Number of subjects: 389

Group type: EXPERIMENTAL
Intervention: Male children
Number of subjects: 389

Group type: EXPERIMENTAL
Intervention: Households with medium wealth terciles
Number of subjects: 389

Group type: EXPERIMENTAL
Intervention: Non-enrolled in schools
Number of subjects: 389
Study: 27269661

Group type: EXPERIMENTAL
Intervention: Fast-acting refrigerant topical agent (applied for 5 seconds)
Number of subjects: 30

Group type: COMPARATOR
Intervention: 20% benzocaine gel topical (applied for 2 minutes)
Number of subjects: 30
Study: 24983321

Group type: EXPERIMENTAL
Intervention: Sofosbuvir plus ribavirin (SOF/RBV)
Number of subjects: 0
Study: 21890591

Group type: EXPERIMENTAL
Intervention: JNJ-37822681 at 5 mg
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: JNJ-37822681 at 10 mg
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: JNJ-37822681 at higher doses (15 mg and 20 mg)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: JNJ-37822681 (various doses)
Number of subjects: 27
Study: 21144971

Group type: EXPERIMENTAL
Intervention: Intensive tailored PAD-specific counseling intervention
Number of subjects: 124

Group type: COMPARATOR
Intervention: Minimal intervention
Number of subjects: 124
Study: 17386348

Group type: EXPERIMENTAL
Intervention: Enalapril treatment for 2.5 years
Number of subjects: 36
Study: 15446674

Group type: EXPERIMENTAL
Intervention: Ketamine (Group-PK)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Nitrous oxide (Group-PN)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Propofol alone (Group-P)
Number of subjects: 25
Study: 11431653

Group type: EXPERIMENTAL
Intervention: 12-hour myoglobin < or = 239 ng/mL
Number of subjects: 839

Group type: EXPERIMENTAL
Intervention: 12-hour troponin-I > 81.5 ng/mL
Number of subjects: 839

Group type: EXPERIMENTAL
Intervention: 12-hour CK-MB > 191 ng/mL
Number of subjects: 839

Group type: COMPARATOR
Intervention: 12-hour myoglobin > 239 ng/mL
Number of subjects: 839

Group type: COMPARATOR
Intervention: 12-hour troponin-I < or = 81.5 ng/mL
Number of subjects: 839

Group type: COMPARATOR
Intervention: 12-hour CK-MB < or = 191 ng/mL
Number of subjects: 839
Study: 9672343

Group type: EXPERIMENTAL
Intervention: Single hyperphosphate enema 1 h before the procedure
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Hyperphosphate enema given 1 and 2 h before the procedure
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Hyperphosphate enema administered 1 and 2 h before the procedure, preceded by a 296 ml bottle of magnesium citrate taken p.o. the night before
Number of subjects: 164
Study: 7974313

Group type: EXPERIMENTAL
Intervention: Salmeterol xinafoate 50 micrograms twice daily
Number of subjects: 427

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 427
Study: 2690316

Group type: EXPERIMENTAL
Intervention: SMS 201-995 (200 micrograms, subcutaneously, 1 ml, three times within 16 hours)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Isotone saline (control, subcutaneously, 1 ml, three times within 16 hours)
Number of subjects: 6
Study: 779797

Group type: EXPERIMENTAL
Intervention: Colchicine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30654697

Group type: EXPERIMENTAL
Intervention: EmoBio
Number of subjects: 83

Group type: COMPARATOR
Intervention: Cognitive measures (MCCB and WAIS-IV)
Number of subjects: 83
Study: 27918396

Group type: EXPERIMENTAL
Intervention: Personalized PALs (Rodenstock Impression FreeSign 3)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Conventional PALs (Rodenstock Progressiv Life Free)
Number of subjects: 51
Study: 25738850

Group type: EXPERIMENTAL
Intervention: ATX-101 (2 mg/cm2, total dose 100 mg)
Number of subjects: 24
Study: 24582846

Group type: EXPERIMENTAL
Intervention: Below-elbow cast excluding the thumb
Number of subjects: 62

Group type: COMPARATOR
Intervention: Below-elbow cast including the thumb
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 62
Study: 21733283

Group type: EXPERIMENTAL
Intervention: D-serine (DSR) 30 mg/kg.d
Number of subjects: 10
Study: 19117329

Group type: EXPERIMENTAL
Intervention: Home-based multi-behavior intervention focused on exercise and a low saturated fat, plant-based diet
Number of subjects: 641

Group type: EXPERIMENTAL
Intervention: Home-based multi-behavior intervention
Number of subjects: 641
Study: 17322163

Group type: EXPERIMENTAL
Intervention: Clinical pharmacist-directed patient education (EDU group)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Routine medical and nursing care (No EDU group)
Number of subjects: 114
Study: 15073698

Group type: EXPERIMENTAL
Intervention: Preoperative heparin therapy (POHI group)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (CONT)
Number of subjects: 46
Study: 11576496

Group type: EXPERIMENTAL
Intervention: Teleconsultation (teleneurology)
Number of subjects: 168

Group type: COMPARATOR
Intervention: Conventional consultation
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Comparison of costs
Number of subjects: 168
Study: 9589675

Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (rhGH) therapy (approximately 0.22 IU/kg.week) for 24 months
Number of subjects: 18
Study: 7604796

Group type: EXPERIMENTAL
Intervention: Fluvastatin monotherapy (40 mg/day)
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Fluvastatin monotherapy (30.2 mg/day)
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Fluvastatin (39.3 mg/day) plus cholestyramine (10.3 mg/day)
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Fluvastatin monotherapy (32.5 mg/day)
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Fluvastatin monotherapy
Number of subjects: 147
Study: 2191507

Group type: EXPERIMENTAL
Intervention: Intravenous nifedipine (0.8-1.0 mg)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo (control group, n = 8)
Number of subjects: 29
Study: 506972

Group type: EXPERIMENTAL
Intervention: Continental type breakfast served with coffee (standardized against reference dose of 3 mg Fe from derrous ascorbate)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Breakfast with tea
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: Breakfast with orange juice
Number of subjects: 129
Study: 30529583

Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation (FMT)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo enemas
Number of subjects: 81
Study: 28164407

Group type: EXPERIMENTAL
Intervention: BUP‐NLX taper
Number of subjects: 125
Study: 25510446

Group type: EXPERIMENTAL
Intervention: 70‐kVp and CM 64 mL
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: 70‐kVp and CM 40 mL
Number of subjects: 69

Group type: COMPARATOR
Intervention: 120‐kVp and CM 64 mL
Number of subjects: 69
Study: 25307707

Group type: EXPERIMENTAL
Intervention: 30 ml ropivacaine 7.5 mg/ml (R group)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Saline (C group)
Number of subjects: 50
Study: 22050141

Group type: EXPERIMENTAL
Intervention: 24 weeks of peginterferon alfa-2a plus ribavirin
Number of subjects: 236

Group type: COMPARATOR
Intervention: 48 weeks of peginterferon alfa-2a plus ribavirin
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: 36 weeks of peginterferon alfa-2a plus ribavirin
Number of subjects: 236

Group type: EXPERIMENTAL
Intervention: 72 weeks of peginterferon alfa-2a plus ribavirin
Number of subjects: 236
Study: 19470469

Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 0
Study: 17617808

Group type: EXPERIMENTAL
Intervention: Ciclesonide 160 microg once daily
Number of subjects: 621

Group type: COMPARATOR
Intervention: Budesonide 400 microg once daily
Number of subjects: 621
Study: 15130462

Group type: EXPERIMENTAL
Intervention: Early imaging
Number of subjects: 782

Group type: COMPARATOR
Intervention: Control group (no early imaging)
Number of subjects: 782
Study: 11936570

Group type: EXPERIMENTAL
Intervention: Clarithromycin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 0
Study: 9718191

Group type: EXPERIMENTAL
Intervention: UV-B irradiation at half the minimal erythemal dose of the lower back, three times per week during 12 weeks
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Oral vitamin D3 400 IU/day during 12 weeks
Number of subjects: 45

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 45
Study: 7651075

Group type: EXPERIMENTAL
Intervention: Synthesized all‐trans beta‐carotene (60 mg daily)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Naturally‐occurring beta‐carotene derived from Dunaliella bardawil
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 2717353

Group type: EXPERIMENTAL
Intervention: Demand Group (exaggerated facial expressions)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Contradictory Expression Group (contradictory facial expressions)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Nondemand Group (no instructions about facial expressions)
Number of subjects: 56
Study: 393047

Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 30897297

Group type: EXPERIMENTAL
Intervention: Prophylactic absorbable polyglactin (Vicryl®) mesh reinforcement
Number of subjects: 69

Group type: COMPARATOR
Intervention: No mesh reinforcement (control group)
Number of subjects: 69
Study: 31425930

Group type: EXPERIMENTAL
Intervention: Past-year opioid misuse
Number of subjects: 130

Group type: COMPARATOR
Intervention: Other substances or alcohol use
Number of subjects: 130
Study: 28012026

Group type: EXPERIMENTAL
Intervention: ARA (Arachidonic acid)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: ARA + ASA (Acetylsalicylic acid)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: ARA
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: ARA + ASA
Number of subjects: 3

Group type: COMPARATOR
Intervention: ARA-free (control)
Number of subjects: 3
Study: 25409110

Group type: EXPERIMENTAL
Intervention: Home DLMOs
Number of subjects: 35

Group type: COMPARATOR
Intervention: Laboratory DLMOs
Number of subjects: 35
Study: 23611079

Group type: EXPERIMENTAL
Intervention: Parent Training (PT)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Waitlist Control (WL)
Number of subjects: 31
Study: 21942184

Group type: EXPERIMENTAL
Intervention: Catgut implantation
Number of subjects: 120

Group type: COMPARATOR
Intervention: Medication (Tramadol Hydrochloride Capsules 100 mg)
Number of subjects: 120
Study: 19826294

Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) with shoes at 2 mm amplitude
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) without shoes at 2 mm amplitude
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) with shoes at 4 mm amplitude
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV) without shoes at 4 mm amplitude
Number of subjects: 10

Group type: COMPARATOR
Intervention: Unloaded isometric half squat (without WBV)
Number of subjects: 10
Study: 17108815

Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 344
Study: 17561541

Group type: EXPERIMENTAL
Intervention: Active CPAP therapy
Number of subjects: 1100

Group type: COMPARATOR
Intervention: Sham (subtherapeutic) CPAP
Number of subjects: 1100
Study: 14717308

Group type: EXPERIMENTAL
Intervention: Intrauterine lignocaine
Number of subjects: 53

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study: 10389123

Group type: EXPERIMENTAL
Intervention: 0.1% diclofenac plus 0.3% tobramycin
Number of subjects: 10

Group type: COMPARATOR
Intervention: Voltaren (diclofenac sodium)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Physiological Saline Braun
Number of subjects: 10

Group type: COMPARATOR
Intervention: Tobrex (tobramycin sulfate)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control 0.3% tobramycin solution
Number of subjects: 10
Study: 9049706

Group type: EXPERIMENTAL
Intervention: Iloprost treatment
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 1725068

Group type: EXPERIMENTAL
Intervention: 6 MU (= 10.4 mg) BM 06.022
Number of subjects: 7

Group type: COMPARATOR
Intervention: Vehicle (placebo)
Number of subjects: 7
Study: 6847852

Group type: EXPERIMENTAL
Intervention: Fructose, 50 g as a 10% solution
Number of subjects: 16

Group type: COMPARATOR
Intervention: Sucrose, 50 g as a 10% solution
Number of subjects: 16
Study: 31959167

Group type: EXPERIMENTAL
Intervention: Budesonide/formoterol 160/4.5 μg
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study: 30107437

Group type: EXPERIMENTAL
Intervention: Allopurinol dose escalation (DE)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Baseline SU ⩾ 8 mg/dl
Number of subjects: 150
Study: 28557902

Group type: EXPERIMENTAL
Intervention: Cryopreserved amniotic (cAM) tissue
Number of subjects: 80

Group type: COMPARATOR
Intervention: No tissue (control)
Number of subjects: 80
Study: 25920338

Group type: EXPERIMENTAL
Intervention: Segmental rotational grade V manipulation (manipulation)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Repeated lumbar extension in lying exercise (EIL)
Number of subjects: 50
Study: 24139772

Group type: EXPERIMENTAL
Intervention: Park-director intervention (PD-only)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: PAB intervention (PAB/PD)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 50
Study: 21047544

Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 31

Group type: COMPARATOR
Intervention: Olanzapine
Number of subjects: 31

Group type: COMPARATOR
Intervention: Perospirone
Number of subjects: 31
Study: 18261680

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stents (SES)
Number of subjects: 310

Group type: COMPARATOR
Intervention: Bare-metal stents (BMS)
Number of subjects: 310
Study: 16749570

Group type: EXPERIMENTAL
Intervention: High pressure pneumoperitoneum (12‐14mmHg)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Low pressure pneumoperitoneum (6‐8mmHg)
Number of subjects: 20
Study: 15222589

Group type: EXPERIMENTAL
Intervention: Standard dose of alcohol (0.34 g/kg women; 0.4 g/kg men)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study: 11142528

Group type: EXPERIMENTAL
Intervention: alpha-tocopherol (50 mg)
Number of subjects: 29133

Group type: EXPERIMENTAL
Intervention: beta-carotene (20 mg)
Number of subjects: 29133

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 29133
Study: 9451581

Group type: EXPERIMENTAL
Intervention: Systemic injections of adrenergic antagonist L657,743
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mixed modality oddball paradigm with auditory context
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mixed modality oddball paradigm with visual context
Number of subjects: 0
Study: 8395716

Group type: EXPERIMENTAL
Intervention: LMWH prophylaxis once a day
Number of subjects: 253

Group type: COMPARATOR
Intervention: No prophylaxis
Number of subjects: 253
Study: 2943195

Group type: EXPERIMENTAL
Intervention: Ticlopidine (250 mg b.i.d.)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 31923367

Group type: EXPERIMENTAL
Intervention: Normobaric Hypoxia (NH)
Number of subjects: 8
Study: 29929055

Group type: EXPERIMENTAL
Intervention: One-hour afternoon nap
Number of subjects: 39

Group type: COMPARATOR
Intervention: No nap (control group)
Number of subjects: 39
Study: 27786516

Group type: EXPERIMENTAL
Intervention: mPE
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: mPE + MET-PTSD
Number of subjects: 126

Group type: COMPARATOR
Intervention: HLS (control)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: mPE and mPE + MET-PTSD
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 126
Study: 25050591

Group type: EXPERIMENTAL
Intervention: Infliximab 3 mg/kg infused at Weeks 0, 2, 6, 14, and 22, with escalation to 5 or 7 mg/kg based on EULAR response at Weeks 14 and 22.
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Infliximab 3 mg/kg with dose escalation based on EULAR response.
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Infliximab treatment with dose escalation.
Number of subjects: 203
Study: 22575081

Group type: EXPERIMENTAL
Intervention: Lifestyle education videoconferences
Number of subjects: 60

Group type: COMPARATOR
Intervention: Comparison group (no intervention)
Number of subjects: 60
Study: 20829151

Group type: EXPERIMENTAL
Intervention: Composites filled with nanoparticles
Number of subjects: 41

Group type: COMPARATOR
Intervention: Microhybrid composite
Number of subjects: 41
Study: 18372037

Group type: EXPERIMENTAL
Intervention: Empress II crowns
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Conventional metal‐ceramic crowns
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Metal-ceramic crowns with framework ending 2mm coronal to the axiogingival line angle
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Try-in pastes used in all test groups
Number of subjects: 36
Study: 15948536

Group type: EXPERIMENTAL
Intervention: Educational program on sun exposure
Number of subjects: 1945

Group type: COMPARATOR
Intervention: Control group (no educational program)
Number of subjects: 1945
Study: 12654955

Group type: EXPERIMENTAL
Intervention: CR oxycodone (10 mg tablet every 12 hours, max 60 mg every 12 hours)
Number of subjects: 159

Group type: COMPARATOR
Intervention: Placebo (identical tablet every 12 hours)
Number of subjects: 159

Group type: EXPERIMENTAL
Intervention: CR oxycodone
Number of subjects: 159

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 159
Study: 11189670

Group type: EXPERIMENTAL
Intervention: Control + pain booklet
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Control + pain booklet and interview
Number of subjects: 45

Group type: COMPARATOR
Intervention: Generic hospital booklet and videotape (control)
Number of subjects: 45
Study: 8857383

Group type: EXPERIMENTAL
Intervention: Two-factor model indicating 'general dependence' and 'failed cessation' dimension
Number of subjects: 394
Study: 1726003

Group type: EXPERIMENTAL
Intervention: 4 mg of lacidipine once daily (n = 220)
Number of subjects: 435

Group type: COMPARATOR
Intervention: 20 mg of nifedipine SR twice daily (n = 215)
Number of subjects: 435

Group type: EXPERIMENTAL
Intervention: 6 mg of lacidipine once daily (n = 82)
Number of subjects: 435

Group type: COMPARATOR
Intervention: 40 mg of nifedipine SR twice daily (n = 62)
Number of subjects: 435

Group type: EXPERIMENTAL
Intervention: 50 mg of atenolol once daily (n = 32)
Number of subjects: 435

Group type: COMPARATOR
Intervention: 50 mg of atenolol once daily (n = 23)
Number of subjects: 435
Study: 6486846

Group type: EXPERIMENTAL
Intervention: Hydrocolloid (HC) occlusive dressing (DuoDerm)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Hydrocolloid (HC) dressing
Number of subjects: 22

Group type: COMPARATOR
Intervention: Mild topical antimicrobial wet dressings (Sweitzer's 1:32 solution)
Number of subjects: 22
Study: 31517967

Group type: EXPERIMENTAL
Intervention: High social support
Number of subjects: 866

Group type: EXPERIMENTAL
Intervention: Natural mentoring
Number of subjects: 866
Study: 30371329

Group type: EXPERIMENTAL
Intervention: Remote Ischemic Preconditioning (RIPC)
Number of subjects: 30
Study: 26758677

Group type: EXPERIMENTAL
Intervention: Minilaparotomy cholecystectomy (MC)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Laparoscopic cholecystectomy (LC)
Number of subjects: 106
Study: 25128594

Group type: EXPERIMENTAL
Intervention: Topical loteprednol etabonate and eyelid scrubs with warm compresses (Group I)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Eyelid scrubs with warm compresses alone (Group II)
Number of subjects: 70
Study: 22669848

Group type: EXPERIMENTAL
Intervention: Intravitreal pegaptanib (Macugen® 0.3 mg = 0.02 mL) combined with conventional diode laser photocoagulation in group 1 (68 eyes of 34 infants)
Number of subjects: 152

Group type: COMPARATOR
Intervention: Conventional laser therapy combined with cryotherapy in group 2 (84 eyes of 42 infants)
Number of subjects: 152
Study: 21182350

Group type: EXPERIMENTAL
Intervention: Darunavir/ritonavir (DRV/r)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control PI-based HAART
Number of subjects: 0
Study: 18353886

Group type: EXPERIMENTAL
Intervention: Eccentric exercise (300 eccentric-concentric actions)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Concentric exercise (300 concentric actions)
Number of subjects: 7